Palvella Therapeutics (PVLA) Share-based Compensation (2016 - 2024)
Historic Share-based Compensation for Palvella Therapeutics (PVLA) over the last 10 years, with Q4 2024 value amounting to $268000.0.
- Palvella Therapeutics' Share-based Compensation rose 11167.76% to $268000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $830000.0, marking a year-over-year increase of 3764.51%. This contributed to the annual value of $830000.0 for FY2024, which is 3764.51% up from last year.
- Palvella Therapeutics' Share-based Compensation amounted to $268000.0 in Q4 2024, which was up 11167.76% from $199000.0 recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Share-based Compensation ranged from a high of $1.4 million in Q3 2020 and a low of -$2.3 million during Q4 2023
- For the 5-year period, Palvella Therapeutics' Share-based Compensation averaged around $807000.0, with its median value being $1.1 million (2020).
- As far as peak fluctuations go, Palvella Therapeutics' Share-based Compensation plummeted by 34183.35% in 2023, and later soared by 11167.76% in 2024.
- Palvella Therapeutics' Share-based Compensation (Quarter) stood at $1.2 million in 2020, then rose by 12.44% to $1.3 million in 2021, then decreased by 28.11% to $949000.0 in 2022, then plummeted by 341.83% to -$2.3 million in 2023, then soared by 111.68% to $268000.0 in 2024.
- Its Share-based Compensation was $268000.0 in Q4 2024, compared to $199000.0 in Q3 2024 and $217000.0 in Q2 2024.